Special Issue "Personalized Therapy in Non-Small Cell Lung Cancer: The Role of Biological Agents and Immunotherapy"
Deadline for manuscript submissions: closed (10 December 2018)
It is no longer acceptable to lump lung cancer into either small cell or non-small cell groups. With the advent of targeted therapy for cancers with mutations or rearrangements, and the increasing role for immunotherapy, there is an increasing need for precise pathology assessment and individualized therapy. This is an exciting time in lung cancer care, but these developments also require clinicians involved in lung cancer to be up to date with all new developments. Hopefully this Special Issue will assist clinicians in being aware of state-of-the-art lung cancer care.
Prof. David J. Barnes
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Personalized therapy
- Targeted therapy
- Lung cancer
- Biological agents
- Non-small cell
- Pathology assessment